Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

BPDCN

- PMLiVE

A New Era in Patient Recruitment & Retention

Innovative Trials launches ‘first of its kind’ service to boost clinical trial patient recruitment and retention .

Innovative Trials

Ten ways to start (or continue) your patient engagement journey

Here are 10 easy approaches Pharma teams can take when starting (or continuing) their patient engagement journey!

Impetus Digital

- PMLiVE

Pfizer announces FDA approval for Braftovi/Mektovi combination in lung cancer

Non-small cell lung cancer accounts for approximately 85% of all lung cancers cases

Picture from the DPharm conference alongside text and branding

DPHARM2023 – Five key themes impacting clinical trials today

Throughout three fascinating days of conference, some key themes emerged that are impacting study teams and the effectiveness of their clinical trials on a daily basis.

Cuttsy + Cuttsy

Navigator – Revolutionize your patient recruitment and retention

Welcome to the new era in patient recruitment and retention

Innovative Trials

- PMLiVE

Pfizer’s Abrysvo RSV vaccine recommended by US CDC for infants

The recommendation allows Abrysvo to be given to pregnant women from 32 to 36 weeks

- PMLiVE

Pfizer’s Litfulo approved by EC for adults and adolescents with severe alopecia areata

The autoimmune disease affects approximately 147 million people globally

- PMLiVE

Date set for EU antitrust regulators to decide on Pfizer’s $43bn Seagen acquisition

The proposed transaction would mark a significant boost to the US pharma’s oncology pipeline

- PMLiVE

FDA approves Pfizer/BioNTech and Moderna’s updated COVID-19 vaccines

The vaccines have both been adapted to target the currently circulating XBB.1.5 Omicron variant

- PMLiVE

Pfizer and BioNTech’s XBB.1.5-adapted COVID-19 vaccine approved by MHRA

The updated vaccine proved effective against the currently circulating XBB.1.5 subvariant

- PMLiVE

Pfizer and BioNTech’s XBB.1.5-adapted COVID-19 vaccine approved by EC

The vaccine is approved for use in adults, children and infants over six months

- PMLiVE

Pfizer and BioNTech’s XBB.1.5-adapted COVID-19 vaccine recommended by CHMP

Doses will be ready to ship immediately upon authorisation by the European Commission

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links